Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Weber PC and Sellmayer A | Modification of the eicosanoid system and cell signalling by precursor fatty acids. | 1991 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:1825543 |
Balazy M et al. | A novel method for the analysis of PAF and alkyl-ether phospholipids by mass spectrometry. | 1991 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:1825562 |
Magni F et al. | Determination of platelet-activating factor in biological samples by high resolution mass spectrometry. | 1991 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:1825563 |
Coceani F et al. | Leukotrienes in cerebrospinal fluid of the conscious cat: effect of platelet-activating factor and pyrogens. | 1991 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:1825586 |
Shen TY et al. | Recent development of platelet-activating factor antagonists. | 1989 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2546389 |
Handley DA et al. | Chemistry and pharmacology of PAF antagonists. Evaluation of changes at potential metabolism sites on activity and duration of activity. | 1989 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2546390 |
Dray F et al. | Recent studies on icosanoids and PAF-acether modulation of some central neurosecretions in the rat. | 1989 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2546391 |
Desquand S et al. | Interference of the PAF-acether antagonist BN 52021 with anaphylaxis in the guinea pig. | 1987 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2445183 |
Benveniste J | PAF-acether (platelet-activating factor). | 1989 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2526498 |
Bussolino F et al. | Chick retina generates platelet-activating factor. | 1987 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2890284 |
Braquet P et al. | Platelet-activating factor: a potential mediator of shock. | 1987 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2960197 |
Myers A et al. | Pharmacological manipulation of platelet-activating factor toxicity in rodents. | 1987 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2960198 |
Benveniste J | Paf-acether (platelet-activating factor). | 1985 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:3159192 |
Livio M et al. | A platelet-activating factor receptor antagonist protects against renal function deterioration in nephrotoxic nephritis. | 1987 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2823570 |
Vargaftig BB et al. | Synergized activation of human platelets by epinephrine and platelet-activating factor-acether is adenosine diphosphate and thromboxane A2-independent. | 1983 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:6221558 |
Voelkel NF et al. | Platelet-activating factor causes pulmonary vasoconstriction and edema via platelet-independent leukotriene formation. | 1983 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:6221590 |
Izumi T et al. | Regulation and signal transduction of PAF receptor. | 1995 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:7732892 |
Bennett SA and Birnboim HC | Platelet activating factor induces transformation of human fibroblasts. | 1995 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:7732893 |
Summers JB et al. | ABT-299, a potent antagonist of platelet activating factor. | 1995 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:7732895 |
Benveniste J | Platelet-activating factor (PAF-acether): present status. | 1981 | Agents Actions | pmid:6176101 |